Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
paclitaxel + ifosfamide + carboplatin + etoposide (N.N. Petrov National Medical Research Center of Oncology)
- Development stage
- Phase 2
- Lead developer
- N.N. Petrov National Medical Research Center of Oncology
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
The TI-CE regimen is a high-dose chemotherapy protocol consisting of paclitaxel, ifosfamide, carboplatin, and etoposide, used in conjunction with autologous stem cell transplantation (ASCT). This specific sequence, evaluated by the N.N. Petrov National Medical Research Center of Oncology, involves two cycles of TI (paclitaxel and ifosfamide) for stem cell mobilization and three cycles of high-dose CE (carboplatin and etoposide) as consolidation therapy. It is primarily indicated for patients with relapsed or refractory germ cell tumors, particularly those who have failed first-line platinum-based chemotherapy. The regimen's efficacy relies on the synergistic effects of microtubule stabilization (paclitaxel), DNA alkylation (ifosfamide and carboplatin), and topoisomerase II inhibition (etoposide) to overcome the resistance mechanisms typically found in advanced germ cell malignancies.
- Other names
- TI-CE regimenHigh-dose TI-CEHigh-dose chemotherapy (TI-CE)
02
Targets
DNATOP2A (DNA topoisomerase II)TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on paclitaxel + ifosfamide + carboplatin + etoposide (N.N. Petrov National Medical Research Center of Oncology).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on paclitaxel + ifosfamide + carboplatin + etoposide (N.N. Petrov National Medical Research Center of Oncology).